Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BioAge Labs, Inc. BIOA

Healthcare  —  Drug Manufacturers Specialty & Generic
7.05 (0.16) (2.22%) as of 25 Sep
Market cap
$337.4M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

BioAge Labs, Inc. (BIOA) Business Profile

Updated before January 2025

Company Overview

BioAge Labs, Inc. (BIOA) is a biotechnology company dedicated to developing therapies that target the biological mechanisms of aging to extend healthy human lifespan. Founded in 2015 by Kristen Fortney, Ph.D., and Eric Morgen, the company is headquartered in Richmond, California. BioAge leverages a proprietary platform that integrates machine learning, omics data, and human biobanks to identify key molecular drivers of aging and age-related diseases. The company’s leadership team includes CEO Kristen Fortney, who has a background in computational biology, and a board of directors composed of seasoned professionals in biotechnology, pharmaceuticals, and venture capital.

Since its inception, BioAge has focused on translating its discoveries into clinical-stage therapies. The company has raised significant funding from prominent investors, including Andreessen Horowitz, Kaiser Permanente Ventures, and Felicis Ventures, to support its mission of combating aging-related diseases.

Core Business Segments

Therapeutics Development

BioAge’s primary focus is on developing therapeutics that target the biological pathways of aging. The company’s pipeline includes:

  • BGE-117: A small molecule inhibitor targeting hypoxia-inducible factor prolyl hydroxylase (HIF-PH), currently in clinical trials for anemia and muscle weakness in older adults.
  • BGE-175: A drug candidate targeting the PGD2 DP1 pathway, aimed at improving immune function in older adults and reducing susceptibility to infections such as influenza.

Data-Driven Discovery Platform

BioAge’s proprietary platform integrates:

  • Machine Learning Algorithms: To analyze large-scale omics datasets and identify biomarkers of aging.
  • Human Biobank Data: Leveraging longitudinal data from human cohorts to uncover molecular targets linked to longevity and age-related diseases.

Collaborative Research

BioAge collaborates with academic institutions, pharmaceutical companies, and research organizations to accelerate the development of aging-related therapies. These partnerships enable the company to expand its research capabilities and validate its findings.

Business Model

BioAge operates on a hybrid business model that combines proprietary drug development with collaborative research. The company generates revenue through:

  1. Therapeutics Commercialization: Licensing its drug candidates to pharmaceutical companies or bringing them to market independently.
  2. Partnerships and Collaborations: Establishing research agreements with academic and industry partners to co-develop therapies and share intellectual property.
  3. Grant Funding: Securing non-dilutive funding from government agencies and non-profit organizations to support its research initiatives.

By integrating its data-driven discovery platform with clinical development, BioAge aims to create a sustainable pipeline of therapies that address the root causes of aging and age-related diseases.

Strategic Direction

BioAge’s strategic priorities include:

  • Expanding the Therapeutics Pipeline: Advancing existing drug candidates through clinical trials and identifying new targets for intervention.
  • Global Market Penetration: Establishing a presence in international markets to address the growing demand for aging-related therapies.
  • Sustainability Goals: Incorporating environmentally sustainable practices in its research and development processes.
  • Exploring New Product Categories: Investigating opportunities in adjacent fields such as regenerative medicine and personalized healthcare.

The company is committed to maintaining its leadership in the aging therapeutics space by continuously innovating and adapting to emerging scientific and market trends.

Competitive Landscape

BioAge operates in a highly competitive biotechnology sector, facing competition from companies such as:

  • Unity Biotechnology: Focused on developing senolytic therapies to eliminate senescent cells.
  • Calico Life Sciences: A Google-backed company researching the biology of aging and age-related diseases.
  • Juvenescence: Developing a broad portfolio of therapies targeting aging mechanisms.
  • ResTORbio: Specializing in mTOR pathway inhibitors to enhance immune function in older adults.

Despite the competition, BioAge differentiates itself through its data-driven approach and focus on human biobank data, which provides unique insights into the biology of aging.

Risk Factors

BioAge faces several risks that could impact its operations and growth:

  1. Regulatory Challenges: Navigating the complex regulatory landscape for aging-related therapies.
  2. Market Dependence: Reliance on the success of its drug candidates to generate revenue.
  3. Supply Chain Disruptions: Potential delays in sourcing raw materials and manufacturing drug candidates.
  4. Competition: Intense competition from established and emerging players in the biotechnology sector.
  5. Funding Risks: Dependence on external funding to support research and development activities.

Recent Developments

In recent years, BioAge has achieved several milestones:

  • Clinical Trials: Progressing BGE-117 and BGE-175 through Phase 1 and Phase 2 clinical trials.
  • Partnerships: Collaborating with leading pharmaceutical companies to co-develop therapies.
  • Technological Advancements: Enhancing its data-driven discovery platform with advanced machine learning techniques.
  • Global Developments: Adapting to the challenges posed by the COVID-19 pandemic, including disruptions to clinical trials and supply chains.

These developments underscore BioAge’s commitment to advancing its mission and maintaining its competitive edge.

Investment Considerations

Strengths

  • Innovative Platform: A proprietary data-driven discovery platform that provides a competitive advantage.
  • Strong Leadership: Experienced management team with expertise in biotechnology and aging research.
  • Growing Market: Increasing demand for aging-related therapies driven by demographic trends.
  • Robust Pipeline: Promising drug candidates targeting key aging pathways.

Risks

  • Clinical Trial Uncertainty: Potential delays or failures in clinical trials.
  • Regulatory Hurdles: Challenges in obtaining regulatory approval for aging-related therapies.
  • Financial Dependence: Reliance on external funding to sustain operations.

Conclusion

BioAge Labs, Inc. is at the forefront of the biotechnology industry, leveraging cutting-edge technology to develop therapies that target the root causes of aging. With a robust pipeline, innovative platform, and strong leadership, the company is well-positioned to capitalize on the growing demand for aging-related therapies. However, investors should carefully consider the risks associated with clinical development and regulatory challenges. Looking ahead, BioAge’s commitment to innovation and strategic growth initiatives positions it as a key player in the aging therapeutics market.